Want to see SBFM full AI Analyst Report?
SBFM Stock Chart & Stats
$1.14
$0.01(0.89%)
At close: 4:00 PM EDT
$1.14
$0.01(0.89%)
Day’s Range― - ―
52-Week Range$0.19 - $23.20
Previous CloseN/A
Volume3.02K
Average Volume (3M)10.85M
Market Cap
$1.04M
Enterprise Value-$10.19M
Total Cash (Recent Filing)$13.75M
Total Debt (Recent Filing)$678.34K
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Nov 10, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.15
Shares Outstanding4,310,301
10 Day Avg. Volume32,068,556
30 Day Avg. Volume10,853,176
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap-9.78
Enterprise Value/Revenue-0.29
Enterprise Value/Gross Profit-0.97
Enterprise Value/Ebitda1.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.3
Revenue Forecast (FY)$35.40M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage reduces interest-burden pressure and preserves financial flexibility compared with a highly indebted business. This gives Sunshine Biopharma more capacity to direct resources toward development and commercialization while limiting the balance-sheet impact of operating volatility.
Underlying Product Gross MarginA positive gross margin shows that the company’s products generate value above direct costs, even though operating expenses currently prevent overall profitability. If revenue stabilizes and costs become better aligned with sales, this gross-profit base could support improved earnings quality.
Diversified Healthcare PortfolioOperating across pharmaceutical development, generic or prescription products, and consumer health offerings gives Sunshine Biopharma multiple commercialization avenues. This broader portfolio can support strategic flexibility and reduce reliance on a single therapeutic or product category over time.
Bears Say
Sharp Revenue Contraction And Persistent LossesThe sharp revenue decline indicates weakened commercialization momentum, while negative operating and net margins show that the current business scale does not cover its cost base. Without renewed sales growth or sustained cost improvement, profitability remains difficult to achieve over the next several quarters.
Ongoing Cash BurnNegative operating and free cash flow mean the company is consuming cash rather than funding operations internally. Continued deterioration increases reliance on financing or existing resources, potentially limiting investment capacity and leaving the business more exposed if profitability does not improve.
Dilution And Concentrated Governance RiskThe authorized share issuance can materially dilute existing shareholders, while dominant voting control concentrates decision-making with one holder. That combination may reduce minority investors’ influence and make future capital-structure actions more consequential for ownership and governance.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $0.18 and its highest was $23.20 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $1.04M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is Nov 10, 2026 which is in 19 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on Aug 05, 2026. The company reported -$1.15 earnings per share for the quarter, beating the consensus estimate of -$1.2 by $0.05.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is -0.17.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 4,310,301 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$1.15 in its last earnings report, beating expectations of -$1.2. Following the earnings report the stock price went up 1.527%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunshine Biopharma
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
1.58% Insiders
<0.01% Other Institutional Investors
98.42% Public Companies and
Individual Investors